Hypersomnia Foundation

Hypersomnia Foundation has been a member of Linktree for 3 years and joined in October 2022. The social media accounts linked to from Hypersomnia Foundation are: • Instagram • TikTok • YouTube • Email Besides social media accounts, hypersomniafoundation has populated their site with: • IH Day 2026 - #WhereInTheworldIH Graphic Gallery • Hey Sleepyhead • Hypersomnia Foundation YouTube Channel • Caught In This Riptide • Focused Projects Grant for Junior Investigators - AASM Foundation • THE SPOON PROJECT • Hypersomnia Foundation | Official Merchandise | Bonfire • About the ONSTRIDE-2 study • Young Adults with Hypersomnia Group Chat • December UNIGHT – Navigating the holidays • Why 80% of sleep disorders go undiagnosed | Lindsay Scola | TEDxSonomaCounty • 2024 End of Year Campaign Social Media Toolkit • 2024 End of Year Campaign • #BeyondSleepy One Day Conference in Phoenix, AZ | Oct 10th • JULY UNIGHT – *July 27th* register now • August Support4Supporters - August 12th • Illuminate Brain Fog | Sleep Consortium • Narcolepsy With Cataplexy Clinical Research Study • U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1｜Takeda Pharmaceuticals • Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia | Avadel Pharmaceuticals PLC • Enrollment is now open for the ALBA Study • PRIME SURVEY • Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses | Jazz Pharmaceuticals plc • The impact of idiopathic hypersomnia on the social lives of young adults • Share your experiences with idiopathic hypersomnia to help others. • Strategic Research Grant - AASM Foundation • Clinical Trial in Low Sodium Oxybate is open for people with Idiopathic Hypersomnia | Mayo Clinic • Building a Global IH Community: Michelle Chadwick on Advocacy, Awareness, and Australia’s Challenges • Dismissed for Decades: Margie’s 30-Year Journey to an Idiopathic Hypersomnia Diagnosis • Rethinking Success, Safety, and Independence: Conversations for Young Adults With IH with Caitlin • Fighting to Be Heard: Taylor Jackson’s Journey Through Dismissal and Diagnosis with IH • The Future of Treatment with Orexin Agonists With Deborah Hartman, PhD • Navigating College with Idiopathic Hypersomnia with Laura Z. • Insights on Adapting Radical Acceptance and Self Compassion as a PWIH With Caitlin • Breaking Barriers with Patient-Owned Data Platforms With Karmen Trzupek • How CBT May Help Manage Your Symptoms With Dr. Shelby Harris • Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia | Alkermes plc • Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc | Alkermes plc • Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program – Centessa Pharmaceuticals • Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 | Alkermes plc • Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia | Harmony Biosciences • Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy | Avadel Pharmaceuticals • Low-sodium oxybate improved symptoms in adults with idiopathic hypersomnia: A Plain Language Summary of Publication • Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 | Alkermes plc • HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY | Harmony Biosciences • Harmony Biosciences announces exclusive agreement to develop and commercialize TPM-1116 • Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 • Press Release : Rare Sleep Disorder More Prevalent Than Previously Thought • Harmony Biosciences Press Release - FDA Grants Priority Review • Your Donation Makes a Difference - Hypersomnia Foundation • Visit Our Website • Top Resources from the Hypersomnia Foundation • Update or join the CoRDS Patient Registry! • CoRDS Fillable Form • Tips for Supporters - Hypersomnia Foundation • Subscribe to SomnusNooze • Videos & Podcasts - Hypersomnia Foundation • Things to consider when making an emergency medical plan • Anesthesia, Hospitalization and Emergency Planning tool kit • Sleep Hygiene and What It Means for People Who Have Hypersomnias - Hypersomnia Foundation • Health and Prescription Medication Insurance Denials and Appeals • Long-COVID & Sleep Disorders Study Report • I Have IH Campaign Reveals Patient and Supporter Perspectives on the Impact of Idiopathic Hypersomnia | Jazz Pharmaceuticals